Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design

被引：41

作者：

Jones, Spencer B. ^{[1
]}

Pfeifer, Lance A. ^{[1
]}

Bleisch, Thomas J. ^{[1
]}

Beauchamp, Thomas J. ^{[1
]}

Durbin, Jim D. ^{[1
]}

Klimkowski, V. Joseph ^{[1
]}

Hughes, Norman E. ^{[1
]}

Rito, Christopher J. ^{[1
]}

Dao, Yen ^{[1
]}

Gruber, Joseph M. ^{[1
,2
]}

Bui, Hai ^{[1
]}

Chambers, Mark G. ^{[1
]}

Chandrasekhar, Srinivasan ^{[1
]}

Lin, Chaohua ^{[1
]}

McCann, Denis J. ^{[1
]}

Mudra, Daniel R. ^{[1
]}

Oskins, Jennifer L. ^{[1
]}

Swearingen, Craig A. ^{[1
]}

Thirunavukkarasu, Kannan ^{[1
]}

Norman, Bryan H. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[2] Dow AgroSci, Zionsville, IN 46268 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 09期

关键词：

Autotaxin; tool molecule; osteoarthritis; LPA; LYSOPHOSPHATIDIC ACID PRODUCTION; ARTHRITIS; MOTILITY; SITE; LPA;

D O I：

10.1021/acsmedchemlett.6b00207

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In an effort to develop a novel therapeutic agent aimed at addressing the unmet need of patients with osteoarthritis pain, we set out to develop an inhibitor for autotaxin with excellent potency and physical properties to allow for the clinical investigation of autotaxin-induced nociceptive and neuropathic pain. An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM. X-ray crystallography enabled the optimization to a lead compound that demonstrated favorable potency (IC50 = 2 nM), PK properties, and a robust PK/PD relationship.

引用

页码：857 / 861

页数：5

共 50 条

[41] Structure-based drug design:: the discovery of novel nonpeptide orally active inhibitors of human renin
Rahuel, J
Rasetti, V
Maibaum, J
Rüeger, H
Göschke, R
Cohen, NC
Stutz, S
Cumin, F
Fuhrer, W
Wood, JM
Grütter, MG
CHEMISTRY & BIOLOGY, 2000, 7 (07): : 493 - 504
[42] Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance
Ghosh, Arun K.
Sridhar, Perali Ramu
Leshchenko, Sofiya
Hussain, Azhar K.
Li, Jianfeng
Kovalevsky, Andrey Yu.
Walters, D. Eric
Wedekind, Joseph E.
Grum-Tokars, Valerie
Das, Debananda
Koh, Yasuhiro
Maeda, Kenji
Gatanaga, Hiroyuki
Weber, Irene T.
Mitsuya, Hiroaki
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (17) : 5252 - 5261
[43] Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors
Liu Tao
Sun Mao-Tang
Dong Xiao-Wu
Ren Xin
Yang Xin
Du Li-Lin
Hu Yong-Zhou
ACTA PHYSICO-CHIMICA SINICA, 2009, 25 (10) : 2107 - 2112
[44] Structure-based design of novel potent nonpeptide thrombin inhibitors
Hauel, NH
Nar, H
Priepke, H
Ries, U
Stassen, JM
Wienen, W
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) : 1757 - 1766
[45] Structure-based design of a novel class of herbicidal HPPD inhibitors
Viner, Russell
Bhonoah, Yunas
Langford, Mike
Kloer, Daniel
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[46] STRUCTURE-BASED DESIGN OF NOVEL NONPEPTIDIC HIV PROTEASE INHIBITORS
LOVASZ, KD
MORRIS, JK
TOMICH, PK
WATENPAUGH, KD
HOWE, WJ
DOLAK, LA
ROMINES, KR
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 25 - MEDI
[47] Optimization of electrostatic interactions in structure-based drug design.
Kumpf, RA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 367 - COMP
[48] Structure-based drug design
Stroud, RM
FASEB JOURNAL, 1997, 11 (09): : A839 - A839
[49] Structure-based drug design
Henry, CM
CHEMICAL & ENGINEERING NEWS, 2001, 79 (23) : 69 - +
[50] STRUCTURE-BASED DRUG DESIGN
MONTGOMERY, JA
NIWAS, S
CHEMTECH, 1993, 23 (11) : 30 - 37

← 1 2 3 4 5 →